This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from AstraZeneca and Bristol-Myers Squibb.
Renal Cell Carcinoma
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Stanford Health Center
40% of patients develop metastasis after primary surgical resection of localized renal cell carcinoma (RCC); this signifies an unmet need for the treatment of metastatic RCC. The mainstay of treatment has been antiangiogenic agents for previously untreated patients, and nivolumab has been shown to improve survival for patients who received prior antiangiogenic therapy. Details on the clinical trial upon which FDA approval for nivolumab was based on, as well as a case study illustrating how to appropriately manage immune-related dermatitis and arthritis are discussed in this video.
|
|
These activities, certified for CME/CE/CPE credit, are jointly provided by
  |